مجله تاریخ پزشکی - علمی پژوهشی

- Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.

- Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 6th ed. China: Saunders, Elsevier; 2007.

- Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000 May 4;342(18):1350-8.

- Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993 Dec;105(6):1846-56.

- Loza-Tavera H. Monoterpenes in essential oils. Biosynthesis and properties. Adv Exp Med Biol 1999;464:49-62.

- Naghash R. Survey of Ceytotoxic Effects of Aques and Alcoholic Extracts of Trachyspermum copticum on 14 Human Tumor Cell Line [Research] Faculty of Pharmacy, Shahid Beheshti Medical University, Tehran, Iran.; 2007.

- Rasooli I, Fakoor MH, Yadegarinia D, Gachkar L, Allameh A, Rezaei MB. Antimycotoxigenic characteristics of Rosmarinus officinalis and Trachyspermum copticum L. essential oils. Int J Food Microbiol 2008 Feb 29;122(1-2):135-9.

- Saghebdoust M, Azadbakht M, Fazli Bazaz BS. In vitro antibacterial activity of 45 essential oils of Iran native plants. European Journal of Medical Researsh 2007;12:69.

- Assessment of Cell Toxicity. Current Protocols in Toxicology, Basic Protocols 8,2.6.11. Supplement 3. 2005.

Ref Type: Generic

- Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 2003 Feb;21(1):21-32.

- Burghardt I, Tritschler F, Opitz CA, Frank B, Weller M, Wick W. Pirfenidone inhibits TGF-beta expression in malignant glioma cells. Biochem Biophys Res Commun 2007 Mar 9;354(2):542-7.

- Liu H, Peng Y, Liu F, Li J, Chen X, Liu Y, et al. A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-beta1 synthesis and matrix production in human peritoneal mesothelial cells. Cell Biol Int 2007 May;31(5):508-15.

- Peng Y, Liu H, Liu F, Liu Y, Li J, Chen X. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells. Nephrology (Carlton ) 2006 Dec;11(6):516-23.

- Ikeda H, Inao M, Fujiwara K. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Biochem Biophys Res Commun 1996 Oct 14;227(2):322-7.

- Ward MR, Sasahara T, Agrotis A, Dilley RJ, Jennings GL, Bobik A. Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries. Atherosclerosis 1998 Apr;137(2):267-75.

- Kondo N, Fukutomi O, Shinbara M, Orii T. Inhibition of interferon-gamma and interleukin-2 production from lymphocytes stimulated with food antigens by an anti-allergic drug, Tranilast, in patients with food-sensitive atopic dermatitis. Biotherapy 1994;8(1):19-22.

- Isaji M, Miyata H, Ajisawa Y, Yoshimura N. Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats. Life Science 1998;63(4):PL71-PL74.

- Isaji M, Miyata H, Ajisawa Y, Takehana Y, Yoshimura N. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol 1997 Nov;122(6):1061-6.

- Koyama S, Takagi H, Otani A, Suzuma K, Nishimura K, Honda Y. Tranilast inhibits protein kinase C-dependent signalling pathway linked to angiogenic activities and gene expression of retinal microcapillary endothelial cells. Br J Pharmacol 1999 May;127(2):537-45.

- Platten M, Wild-Bode C, Wick W, Leitlein J, Dichgans J, Weller M. N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 2001 Jul 1;93(1):53-61.

- Yashiro M, Chung YS, Sowa M. Tranilast (N-(3,4-dimethoxycinnamoyl) anthranilic acid) down-regulates the growth of scirrhous gastric cancer. Anticancer Res 1997 Mar;17(2A):895-900.

- Murahashi K, Yashiro M, Inoue T, Nishimura S, Matsuoka T, Sawada T, et al. Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer. Int J Oncol 1998 Dec;13(6):1235-40.

- Nie L, Oishi Y, Doi I, Shibata H, Kojima I. Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel. Cell Calcium 1997 Aug;22(2):75-82.

- Yatsunami J, Aoki S, Fukuno Y, Kikuchi Y, Kawashima M, Hayashi SI. Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells. Int J Oncol 2000 Dec;17(6):1151-6.

- Dziegielewska KM, Brown WM, Casey SJ, Christie DL, Foreman RC, Hill RM, et al. The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily. J Biol Chem 1990 Mar 15;265(8):4354-7.

- Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ. Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 1976 Jul 15;262(5565):226-7.

- Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/alpha2-HS glycoprotein is a transforming growth factor-beta type II receptor mimic and cytokine antagonist. J Biol Chem 1996 May 31;271(22):12755-61.

- Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 1990 Jul 19;346(6281):281-4.

- Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994 Sep 1;302 ( Pt 2):527-34.

- Stander M, Naumann U, Dumitrescu L, Heneka M, Loschmann P, Gulbins E, et al. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther 1998 Sep;5(9):1187-94.

- Bottinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, et al. The recombinant proregion of transforming growth factor beta1 (latency-associated peptide) inhibits active transforming growth factor beta1 in transgenic mice. Proc Natl Acad Sci U S A 1996 Jun 11;93(12):5877-82.

- Wilkinson KA, Martin TD, Reba SM, Aung H, Redline RW, Boom WH, et al. Latency-associated peptide of transforming growth factor beta enhances mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL/6 mice. Infect Immun 2000 Nov;68(11):6505-8.

- Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004 Nov 1;64(21):7954-61.

- Brooks SP, Bernstein ZP, Schneider SL, Gollnick SO, Tomasi TB. Role of transforming growth factor-beta1 in the suppressed allostimulatory function of AIDS patients. AIDS 1998 Mar 26;12(5):481-7.